VanEck Biotech ETF (BBH)
| Assets | $472.98M |
| Expense Ratio | 0.35% |
| PE Ratio | 16.73 |
| Shares Out | n/a |
| Dividend (ttm) | $0.71 |
| Dividend Yield | 0.43% |
| Ex-Dividend Date | Dec 18, 2023 |
| Payout Ratio | 7.21% |
| 1-Year Return | +3.15% |
| Volume | 15,300 |
| Open | 166.12 |
| Previous Close | 166.40 |
| Day's Range | 164.96 - 166.23 |
| 52-Week Low | 142.51 |
| 52-Week High | 169.66 |
| Beta | n/a |
| Holdings | 23 |
| Inception Date | Dec 20, 2011 |
About BBH
Fund Home PageThe VanEck Biotech ETF (BBH) is an exchange-traded fund that is based on the MVIS US Listed Biotech 25 index, a market-cap-weighted index of the 25 largest biotech firms globally. BBH was launched on Dec 20, 2011 and is issued by VanEck.
Top 10 Holdings
74.01% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen Inc. | AMGN | 17.36% |
| Vertex Pharmaceuticals Incorporated | VRTX | 10.66% |
| Gilead Sciences, Inc. | GILD | 10.30% |
| Regeneron Pharmaceuticals, Inc. | REGN | 8.26% |
| Moderna, Inc. | MRNA | 5.45% |
| IQVIA Holdings Inc. | IQV | 5.21% |
| Biogen Inc. | BIIB | 4.89% |
| ICON PLC | ICLR | 4.39% |
| argenx SE | ARGX | 3.74% |
| Illumina, Inc. | ILMN | 3.74% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 18, 2023 | $0.7127 | Dec 22, 2023 |
| Dec 19, 2022 | $0.7488 | Dec 23, 2022 |
| Dec 20, 2021 | $0.3972 | Dec 27, 2021 |
| Dec 21, 2020 | $0.6079 | Dec 28, 2020 |
| Dec 23, 2019 | $0.4724 | Dec 30, 2019 |
| Dec 20, 2018 | $0.551 | Dec 27, 2018 |
News
VettaFi Voices On: The Outlook for 2024
Good morning, VettaFi Voices! We are a week out from the VettaFi 2024 Market Outlook Symposium on December 14, which will feature a range of ETF industry leaders discussing their expectations for diff...
Biotech Still Has Disruptive Capabilities
In what feels like an eternity in biotechnology terms, broader baskets of the industry's stocks haven't outperformed the S&P 500 Health Care Index annually since 2020. That streak could end this year,...
Bevy of Biotech Bargains in BBH
Historically, biotechnology stocks trade at premiums relative to the healthcare and the broader market. That's simply the price of admission investors to pay to access the attractive growth prospects ...
Biotech Industry Ripe for AI Disruption
With generative artificial intelligence (AI) seemingly gaining traction by the day, more market participants are evaluating where this innovation fits into their industries. Biotech may be next for di...
VanEck's John Patrick Lee Talks Trends Driving Robotics & IBOT
Earlier this month, VanEck launched the VanEck Robotics ETF (IBOT), a thematic equity ETF offering exposure to the leading global companies that are driving and benefiting from the growth of the robot...
VanEck Launches Robotics ETF
VanEck launched the VanEck Robotics ETF (IBOT), a thematic equity ETF offering exposure to the leading global companies that are driving and benefiting from the growth of the robotics industry. The fu...
Brown Brothers Harriman Private Banking Team Expands in Philadelphia
PHILADELPHIA--(BUSINESS WIRE)--The Private Banking arm of Brown Brothers Harriman & Co. (BBH) is pleased to announce the expansion and strengthening of its Corporate Advisory and Banking team in Phi...
Biotech Finally Getting Its Groove Back
There's still plenty of room to run to return to prior highs, but some biotech stocks and exchange traded funds are showing signs of life. That's encouraging after what has been a surprisingly long do...
Assessing the Strength of Biotech Dividends With BBH
Biotechnology usually isn't the first industry investors think of when it comes to dividends, but some of the more mature companies in the space do deliver payouts. Some of those names reside in the V...
Consolidation Case for Biotech ETF BBH
Eight months into 2022, it's fair to say that it's been a tepid year of deal-making in the biotechnology industry, and that's one reason why the related stocks and exchange traded funds are scuffling.
Biotech Bounce-Back Could Be Durable
Following a lengthy wait that included plenty of downside and frustration, biotechnology stocks and exchange traded funds are finding a groove. For example, the VanEck Vectors Biotech ETF (BBH) is hig...
Biotech Rebound Could Finally Be Afoot
A long-awaited biotechnology equity rebound could be materializing and some analysts believe it could have the momentum to carry into the end of 2022.
Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs
Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in i...
Bank on BBH for Surprising Protection
Owing to its reputation as a growth-heavy industry that's been disappointing investors since early 2021, biotechnology probably isn't the first destination investors think of when seeking shelter-from...
Biotech Stocks, ETFs Could Be Due for Second Half Rallies
Biotechnology stocks and the related exchange traded funds are in a prolonged slump, and along the way, calls for rebounds have been plentiful. They've also proven inaccurate.
Basic Could Be Beautiful When Biotech Bounces Back
Biotechnology stocks and exchange traded funds are into a second year of disappointing investors, but that condition won't be permanent. With that in mind, investors evaluating ideas for a biotech res...
Size Up SBIO as Biotech Catalysts Emerge
Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech ...
Betting on Biotech Bear Market Expiration Date
Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader...
Positioning for Biotech Bounceback
Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that...
Biotech Stocks, ETFs Starting to Look Healthier
Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALP...
Vaccine Stocks Lift Biotech ETFs as China Enters Lockdowns
Biotechnology sector-related exchange traded funds gained on Monday, with Moderna Inc. (NasdaqGS: MRN) sitting among the top performers in the S&P 500, on renewed COVID-19 concerns as China implements...
SBIO Is a Good Place to Be for Biotech Innovation
While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare se...
Biotech ETFs Muddled Despite Amgen Strength
Biotechnology sector-specific exchange traded funds were flat after Amgen (NasdaqGS: AMGN) provided a mixed earnings report but announced that it will return value to investors through greater share b...